| pubmed-article:2257861 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2257861 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2257861 | lifeskim:mentions | umls-concept:C0039771 | lld:lifeskim |
| pubmed-article:2257861 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:2257861 | lifeskim:mentions | umls-concept:C0086045 | lld:lifeskim |
| pubmed-article:2257861 | lifeskim:mentions | umls-concept:C0600260 | lld:lifeskim |
| pubmed-article:2257861 | lifeskim:mentions | umls-concept:C2827666 | lld:lifeskim |
| pubmed-article:2257861 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2257861 | pubmed:dateCreated | 1991-1-30 | lld:pubmed |
| pubmed-article:2257861 | pubmed:abstractText | The predictability and intraindividual variability of serum theophylline concentrations (STC) after different dosing schedules were investigated in 24 patients with chronic obstructive lung disease (COLD). Three oral regimens were compared in 3 groups of 8 randomly assigned patients. Group I:Drug A once daily in the evening; Group II: Drug A b.d.; Group III: Drug B b.d. The doses for each patient were estimated by Bayesian forecasting aiming at an STC of 10-15 mg/l. STC and FEV1 were measured on two consecutive days at steady-state. The day-to-day variability of STC was less than 20% in all three groups. The within-day fluctuation in Group I amounted to 259% (median) compared to 57% and 38% in Groups II and III, respectively. Dose adjustment by Bayesian forecasting resulted in a therapeutic STC in most patients with a b.d. regimen, whereas for the once daily dose the prediction was not satisfactory. No difference in lung function was found between the 24-h and 12-h dosing, probably because of the large intersubject variability in FEV1. Therefore, the question whether the differences in STC profile are of clinical importance in COLD can only be investigated in a larger group of patients. | lld:pubmed |
| pubmed-article:2257861 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2257861 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2257861 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2257861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2257861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2257861 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2257861 | pubmed:issn | 0031-6970 | lld:pubmed |
| pubmed-article:2257861 | pubmed:author | pubmed-author:PerruchoudAA | lld:pubmed |
| pubmed-article:2257861 | pubmed:author | pubmed-author:FollathFF | lld:pubmed |
| pubmed-article:2257861 | pubmed:author | pubmed-author:KellerBB | lld:pubmed |
| pubmed-article:2257861 | pubmed:author | pubmed-author:VozehSS | lld:pubmed |
| pubmed-article:2257861 | pubmed:author | pubmed-author:SchmidlinOO | lld:pubmed |
| pubmed-article:2257861 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2257861 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:2257861 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2257861 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2257861 | pubmed:pagination | 253-6 | lld:pubmed |
| pubmed-article:2257861 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:meshHeading | pubmed-meshheading:2257861-... | lld:pubmed |
| pubmed-article:2257861 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2257861 | pubmed:articleTitle | Predictability and intraindividual variability of serum theophylline concentrations in patients with obstructive lung disease: 12-h versus 24-h dosing. | lld:pubmed |
| pubmed-article:2257861 | pubmed:affiliation | Division of Clinical Pharmacology, University Hospital, Kantonsspital, Basel, Switzerland. | lld:pubmed |
| pubmed-article:2257861 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2257861 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2257861 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2257861 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2257861 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
